Hepagene Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developing oral therapies for a functional cure for chronic hepatitis B.
Infectious DiseaseMetabolic
Technology Platform
Platform for discovering oral small molecules that target multiple stages of the hepatitis B virus lifecycle, with a focus on viral entry and replication.
Opportunities
Huge addressable patient population in Asia and potential for a paradigm shift from suppression to functional cure.
Risk Factors
High clinical and regulatory hurdles for demonstrating a functional cure, and intense competition from well-funded global players.
Competitive Landscape
Competes in the crowded but high-need HBV curative space against large pharma (Gilead, GSK) and biotechs, requiring differentiation through novel mechanisms or superior combo data.